| Conţinutul numărului revistei |
| Articolul precedent |
| Articolul urmator |
 263 0 |
 SM ISO690:2012LANGE, Christoph G., CHESOV, Dumitru, FURIN, Jennifer Joan, UDWADIA, Zarir Farokh, DHEDA, Keertan U.J.. Revising the definition of extensively drug-resistant tuberculosis. In: The Lancet Respiratory Medicine, 2018, vol. 6, pp. 893-895. ISSN 2213-2600. DOI: https://doi.org/10.1016/S2213-2600(18)30428-4 |
| EXPORT metadate: Google Scholar Crossref CERIF DataCite Dublin Core |
  The Lancet Respiratory Medicine |
|
| Volumul 6 / 2018 / ISSN 2213-2600 | |
|
|
| DOI:https://doi.org/10.1016/S2213-2600(18)30428-4 | |
| Pag. 893-895 | |
| Rezumat | |
WHO estimated that in 2017, 460 000 people developed multidrug-resistant (MDR) tuberculosis, defined by bacillary resistance to rifampicin and isoniazid, the two most effective first-line anti-TB drugs. Approximately 8·5% of MDR tuberculosis isolates had additional drug resistance to at least one fluoroquinolone and one of the second-line injectable drugs amikacin, capreomycin and/or kanamycin, which together define extensively-drug resistant (XDR) tuberculosis. |
|
| Cuvinte-cheie Antitubercular Agents, extensively drug-resistant tuberculosis, Global Health, Humans |
|
|
|
|
|
